Stachys schtschegleevii tea, matrix metalloproteinase, and disease severity in female rheumatoid arthritis patients: a randomized controlled clinical trial

  Background Stachys schtschegleevii ( SSC ) is a herbal medicine used to treat infections. To date, this is the first study aimed to investigate the effects of SSC tea on disease activity score (DAS), serum inflammatory biomarkers and matrix metalloproteinases (MMP-1 and MMP-3) among women with rhe...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2022-04, Vol.41 (4), p.1033-1044
Main Authors: Mirtaheri, Elham, Khabbazi, Alireza, Nazemiyeh, Hossein, Ebrahimi, Ali-Asghar, Hajalilou, Mehrzad, Shakibay Novin, Zahra, Pirouzpanah, Saeed
Format: Article
Language:English
Subjects:
Adult
Aged
Arthritis, Rheumatoid - drug therapy
C-reactive protein
Clinical trials
Double-Blind Method
Female
Herbal medicine
Humans
IL-1β
Inflammation
Interleukin 1
Interstitial collagenase
Iran
Joint diseases
Matrix metalloproteinase
Matrix Metalloproteinase 3
Medicine
Medicine & Public Health
Metalloproteinase
Middle Aged
Original Article
Patients
Placebos
Registration
Rheumatoid arthritis
Rheumatology
Serum levels
Severity of Illness Index
Stachys
Stromelysin 1
Tea
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:  Background Stachys schtschegleevii ( SSC ) is a herbal medicine used to treat infections. To date, this is the first study aimed to investigate the effects of SSC tea on disease activity score (DAS), serum inflammatory biomarkers and matrix metalloproteinases (MMP-1 and MMP-3) among women with rheumatoid arthritis (RA). Methods This pilot, triple-blind, randomized controlled clinical trial was conducted among forty-four women (age: 30–65 years) diagnosed with moderately active RA. Subjects were randomly assigned (1:1 ratio) into either SSC group (2.4 g/day SSC + 2.4 g/day black tea, n =22) or placebo (2.4 g/day black tea, n =22) for 8 weeks. Serum high-sensitivity C-reactive protein (hs-CRP), interleukin-1 beta (IL-1β), and MMPs were measured using ELISA. According to the American College of Rheumatology guideline considering hs-CRP, DAS28 was assessed. Results Both study groups had respondent rates above 94.9%. The SSC intervention caused significant reductions in the number and the percent changes of the tender joints ( SSC : −74.39% vs .  placebo: −57.15%, mean differences= −0.77; P
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-021-05981-4